Lupin, TB Alliance partner for new therapy for highly drug-resistant TB
Indian pharma company Lupin Limited has secured a non-exclusive license from TB Alliance, a non-profit drug developer, for manufacturing the anti-TB drug pretomanid. Pretomanid is part of the three-drug BPaL regimen (made up of bedaquiline, pretomanid, and linezolid), intended for the treatment of highly drug-resistant tuberculosis (TB). Mel Spigelman — President and CEO of TB […]